Experimental CAR-T therapy takes on relapsed blood cancers
NCT ID NCT07234045
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing a new treatment called CT1195E CAR-T cells in 30 adults with B-cell blood cancers that have come back or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells. The main goals are to check the safety and find the right dose, while also looking at how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CT1195E CAR-T cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with hard-to-treat B-cell blood cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 30 participants, so it is primarily testing safety and dosing. The therapy may not work well or could cause serious side effects, and it is far from being widely available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, Tianjin Municipality, 301617, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer biopsy predict who responds to a new immunotherapy?
- Can a cheaper copy of a leukemia drug work just as well?
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Immune cells engineered to fight lymphoma enter human testing
- New drug combo shows promise for Tough-to-Treat lymphoma
- New combo therapy shows promise for tough lymphoma cases